As shown in Figure 3B,C as well as Figure 4B,F, the data indicated that the level and positive rate (62.4%, 58/93) of autoantibody to GNAS in early-stage HCC patients was still higher than that (51.5%, 34/66) in late-stage HCC patients even if the difference was not significant, which was in line with the results from the discovery phase. This evidence concerns the gene GNAS and hepatocellular carcinoma.